Options for the medical management of obesity are set to expand with the expected introduction of two new oral GLP-1 receptor agonists into the Australian market.
End of content
No more pages to load
Options for the medical management of obesity are set to expand with the expected introduction of two new oral GLP-1 receptor agonists into the Australian market.
End of content
No more pages to load